Electra Therapeutics raises $350 million in Nasdaq IPO to fund commercial expansion
read at Endpoints ↗DealPositive
Electra Therapeutics announced that it priced its initial public offering on the Nasdaq at $350 million, becoming the 21st biotech to go public in 2026.
The Bay Area‑based company said the capital will be directed toward advancing its pipeline and building commercial capabilities.
CEO Kathy Dong highlighted that the funding positions the firm to transition from a development‑focused biotech to a commercial enterprise.
The offering was completed on Thursday evening, and the shares began trading shortly thereafter.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Electra's $350M IPO will help it become a commercial biotech”
read at Endpoints ↗81 words · retrieved Sep 18
comments(0)
5-min edit window · permanent after that